FDA Grants Traditional Approval to Iptacopan in Primary IgAN - Top-Institutions - MDSpire

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

  • By

  • Kathryn Wighton

  • July 17, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    University of Alabama at Birmingham
    University of Alabama at Birmingham

    Birmingham, AL

    Key Differentiators

    • Nephrology

  • #2

    Thomas Jefferson University
    Thomas Jefferson University

    Philadelphia, PA

    Key Differentiators

    • Nephrology

  • #3

    Ganzhou Hospital-Nanfang Hospital
    Ganzhou Hospital-Nanfang Hospital

    Ganzhou, Jiangxi

    Key Differentiators

    • Nephrology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Nephrology

  • #5

    California Pacific Medical Center
    California Pacific Medical Center

    San Francisco, CA

    Key Differentiators

    • Nephrology

Original Source(s)

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

  • by Kathryn Wighton

  • July 17, 2026

Related Content

Correction: Editorial: Advances in organ-specific autoimmune response: from basics to clinics

Early Nephrology Consultation and Acute Kidney Injury in Hospitalized Patients: A Randomized Clinical Trial

CGM Linked to More Time in Range

In a randomized crossover trial of insulin-treated patients receiving hemodialysis, real-time continuous glucose monitoring did not improve the primary hypoglycemia outcome but increased time in range and reduced time above range vs capillary testing.